![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Elysee Development Corp (PK) | USOTC:ASXSF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.00462 | -1.94% | 0.23362 | 0.193 | 0.3345 | 0.23362 | 0.23362 | 0.23362 | 500 | 21:00:27 |
þ | QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
NEVADA | 86-0837251 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification Number) | |
XAVIER DE COCKLAAN 42, 9831 DEURLE, BELGIUM | N/A | |
(Address of principal executive offices) | (Zip code) |
Page | ||||
3 | ||||
3 | ||||
3 | ||||
4 | ||||
5 | ||||
6 | ||||
8 | ||||
17 | ||||
21 | ||||
22 | ||||
22 | ||||
22 | ||||
22 | ||||
22 | ||||
22 | ||||
23 | ||||
24 |
2
December 31, 2007 | March 31, 2007 | |||||||
(unaudited) | ||||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$ | 2,016,538 | $ | 126,966 | ||||
Accounts receivable, net of allowance for doubtful accounts of $73,940 at December
31, 2007 and $79,996 at March 31, 2007
|
1,583,946 | 1,724,121 | ||||||
Inventories, net
|
1,128,898 | 1,132,941 | ||||||
Prepaid expense
|
1,023,930 | 668,421 | ||||||
Total current assets
|
5,753,312 | 3,652,449 | ||||||
PROPERTY AND EQUIPMENT, NET
|
727,522 | 589,623 | ||||||
OTHER ASSETS
|
||||||||
Long-term investments and advances
|
675,000 | | ||||||
Patents, net
|
123,974 | 135,894 | ||||||
TOTAL ASSETS
|
$ | 7,279,808 | $ | 4,377,966 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Current portion, long term debt
|
$ | 14,443 | $ | 43,499 | ||||
Line of Credit
|
813,344 | 1,530,276 | ||||||
Notes payable
|
| 11,282 | ||||||
Accounts payable
|
1,644,577 | 1,441,502 | ||||||
Accrued liabilities
|
377,182 | 412,435 | ||||||
Due to related parties
|
50,536 | 50,536 | ||||||
Taxes payable
|
81,859 | | ||||||
Total current liabilities
|
2,981,941 | 3,489,530 | ||||||
LONG TERM DEBT
|
149,715 | 152,343 | ||||||
STOCKHOLDERS EQUITY:
|
||||||||
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and
outstanding)
|
| | ||||||
Common stock, $0.001 par value; (50,000,000 shares authorized, 18,606,245 shares
issued and outstanding at December 31, 2007 and 12,996,245 shares issued and
outstanding at March 31, 2007)
|
18,606 | 12,996 | ||||||
Additional paid-in capital
|
17,792,553 | 11,904,000 | ||||||
Accumulated deficit
|
(13,640,049 | ) | (11,147,600 | ) | ||||
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)
|
(22,958 | ) | (33,303 | ) | ||||
Total stockholders equity
|
4,148,152 | 736,093 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
|
$ | 7,279,808 | $ | 4,377,966 | ||||
COMMITMENTS (Note 18)
|
3
For the three months ended | For the nine months ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2007 | 2006 | 2007 | 2006 | |||||||||||||
Net sales
|
$ | 2,132,950 | $ | 1,159,408 | $ | 4,453,899 | $ | 4,870,161 | ||||||||
Cost of sales
|
1,271,430 | 672,050 | 2,623,506 | 2,627,724 | ||||||||||||
Gross profit
|
861,520 | 487,358 | 1,830,393 | 2,242,437 | ||||||||||||
Operating Expenses
|
||||||||||||||||
Research and development
|
172,108 | 63,394 | 247,665 | 303,894 | ||||||||||||
Sales and marketing
|
611,144 | 119,756 | 996,937 | 743,170 | ||||||||||||
General and administrative
|
1,087,313 | 872,042 | 2,891,165 | 2,543,154 | ||||||||||||
Depreciation and amortization
|
80,157 | 59,896 | 215,941 | 147,590 | ||||||||||||
TOTAL OPERATING EXPENSES
|
1,950,722 | 1,115,088 | 4,351,708 | 3,737,808 | ||||||||||||
INCOME (LOSS) FROM OPERATIONS
|
(1,089,202 | ) | (627,730 | ) | (2,521,315 | ) | (1,495,371 | ) | ||||||||
OTHER INCOME (EXPENSES)
|
||||||||||||||||
Interest expense
|
(16,588 | ) | (24,849 | ) | (71,802 | ) | (122,318 | ) | ||||||||
Interest income
|
9,040 | | 100,665 | | ||||||||||||
Other income
|
| 5,016 | | 32,538 | ||||||||||||
TOTAL OTHER INCOME (EXPENSES)
|
(7,548 | ) | (19,833 | ) | 28,863 | (89,780 | ) | |||||||||
NET LOSS
|
$ | (1,096,750 | ) | $ | (647,563 | ) | $ | (2,492,452 | ) | $ | (1,585,151 | ) | ||||
LOSS PER SHARE
|
||||||||||||||||
Basic and fully diluted
|
$ | (0.06 | ) | $ | (0.05 | ) | $ | (0.14 | ) | $ | (0.12 | ) | ||||
WEIGHTED AVERAGE SHARES OUTSTANDING
|
||||||||||||||||
Basic and fully diluted
|
18,602,115 | 12,996,245 | 17,557,700 | 12,963,794 | ||||||||||||
4
For the three months ended | For the nine months ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||||
2007 | 2006 | 2007 | 2006 | |||||||||||||
Net Income (Loss)
|
$ | (1,096,750 | ) | $ | (647,563 | ) | $ | (2,492,452 | ) | $ | (1,585,151 | ) | ||||
OTHER COMPREHENSIVE INCOME (LOSS):
|
||||||||||||||||
Foreign currency translation adjustment
|
58,949 | 31,096 | 10,345 | 56,511 | ||||||||||||
Comprehensive income (loss)
|
$ | (1,037,801 | ) | $ | (616,467 | ) | $ | (2,482,107 | ) | $ | (1,528,640 | ) | ||||
5
For the nine months ended | ||||||||
December 31, | ||||||||
2007 | 2006 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES
|
||||||||
Net loss
|
$ | (2,492,452 | ) | $ | (1,585,151 | ) | ||
Adjustments to reconcile net loss to net cash used by operating activities
|
||||||||
Depreciation and amortization
|
215,941 | 147,590 | ||||||
Allowance for doubtful accounts
|
(13,417 | ) | (2,597 | ) | ||||
Stock issued upon conversion of convertible debentures
|
| 25,706 | ||||||
Value of stock options to employees and consultants
|
101,271 | 221,959 | ||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
137,273 | 990,234 | ||||||
Inventories
|
4,043 | 373,479 | ||||||
Prepaid expenses
|
(352,607 | ) | (357,197 | ) | ||||
Accounts payable
|
203,075 | (366,123 | ) | |||||
Accrued liabilities
|
(35,253 | ) | (177,609 | ) | ||||
Income taxes payable
|
81,859 | (107,783 | ) | |||||
Net cash used by operating activities
|
(2,150,267 | ) | (837,492 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES
|
||||||||
Decrease (increase) in restricted cash
|
| 70,762 | ||||||
Long-term investments
|
(675,000 | ) | | |||||
Purchases of patents
|
(11,998 | ) | | |||||
Purchases of equipment
|
(165,195 | ) | (356,336 | ) | ||||
Net cash used by investing activities
|
(852,193 | ) | (285,574 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES
|
||||||||
Net proceeds from issuance of stock
|
5,792,893 | | ||||||
Principal payments on (proceeds from) capital lease note payable
|
(31,684 | ) | 121,203 | |||||
Note payments related parties
|
| (8,422 | ) | |||||
Proceeds from (repayments of) line of credit
|
(716,932 | ) | 1,024,679 | |||||
Net cash provided by financing activities
|
5,044,277 | 1,137,460 | ||||||
NET INCREASE IN CASH
|
2,041,817 | 14,394 | ||||||
Effect of exchange rate changes on cash and cash equivalents
|
(152,245 | ) | (61,325 | ) | ||||
CASH AND CASH EQUIVALENTS, BEGINNING
|
126,966 | 332,145 | ||||||
CASH AND CASH EQUIVALENTS, ENDING
|
$ | 2,016,538 | $ | 285,214 | ||||
Supplemental Information:
|
||||||||
Interest paid
|
$ | 14,418 | $ | 76,377 | ||||
Income taxes paid
|
$ | | $ | | ||||
6
7
8
9
10
Revenues For the nine month period ended December 31, 2007 the Company had five customers that accounted for 34.20% of total revenues. For the nine months ended December 31, 2006 the Company had one customer that accounted for 41,8 % of total revenues. | ||
5. | ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS | |
A summary of accounts receivable and allowance for doubtful accounts as of December 31, 2007 and March 31, 2007 is as follows: |
December 31, 2007 | March 31, 2007 | |||||||
Accounts receivable, gross
|
$ | 1,657,886 | $ | 1,804,117 | ||||
Less: allowance for doubtful accounts
|
(73,940 | ) | (79,996 | ) | ||||
Accounts receivable, net
|
$ | 1,583,946 | $ | 1,724,121 | ||||
6. | INVENTORIES | |
Inventories are stated at the lower of cost (weighted average) or market. Inventory costs include material, labor and manufacturing overhead. Individual components of inventory are listed below as follows: |
December 31, 2007 | March 31, 2007 | |||||||
Raw materials
|
$ | 34,660 | $ | 30,579 | ||||
Components
|
902,181 | 786,728 | ||||||
Finished goods
|
206,779 | 329,000 | ||||||
|
1,143,620 | 1,146,307 | ||||||
Less: reserve for obsolescence
|
(14,722 | ) | (13,366 | ) | ||||
Net inventory
|
$ | 1,128,898 | $ | 1,132,941 | ||||
7. | PREPAID EXPENSES | |
Prepaid expenses are summarized as follows: |
December 31, 2007 | March 31, 2007 | |||||||
Prepaid materials and components
|
$ | 518,193 | $ | 394,598 | ||||
Prepaid Belgium income taxes
|
73,605 | 66,830 | ||||||
Prepaid consulting
|
98,540 | 66,830 | ||||||
VAT payments in excess of VAT receipts
|
196,388 | 47,260 | ||||||
Royalties
|
36,803 | 33,415 | ||||||
Prepaid trade show expenses
|
45,526 | 6,523 | ||||||
Prepaid rent
|
10,066 | 7,054 | ||||||
Other
|
44,809 | 45,911 | ||||||
|
||||||||
|
$ | 1,023,930 | $ | 668,421 | ||||
|
8. | PROPERTY AND EQUIPMENT | |
Property and equipment are summarized as follows: |
December 31, 2007 | March 31, 2007 | |||||||
Furniture and Fixtures
|
$ | 180,603 | $ | 137,560 | ||||
Machinery and Equipment
|
768,971 | 559,422 | ||||||
Tooling
|
254,450 | 188,450 | ||||||
|
1,204,024 | 885,432 | ||||||
Accumulated depreciation
|
(476,502 | ) | (295,809 | ) | ||||
Property & equipment, net
|
$ | 727,522 | $ | 589,623 | ||||
11
9. | LONG TERM INVESTMENTS AND ADVANCES | |
Innovative Medical & Dental Solutions, LLC (IMDS, LLC) | ||
Effective July 15, 2007 the Company entered into a Limited Liability Company Merger and Equity Reallocation Agreement (the Participation Agreement) through its subsidiary, Remedent N.V. Pursuant to the terms of the Participation Agreement, the Company has acquired a 10% equity interest in IMDS, LLC in consideration for $300,000 which was converted against IMDS receivables. | ||
The agreement stipulates certain exclusive world wide rights to certain tooth whitening technology, and the right to purchase at standard cost certain whitening lights and accessories and to sell such lights in markets not served by the LLC. The terms of the Participation Agreement also provide that Remedent N.V. has the first right to purchase additional equity. Parties to the Participation Agreement include two officers of IMDS, LLC, and an individual who is both an officer and director of Remedent Inc., and certain unrelated parties. | ||
IMDS, LLC is registered with the Secretary of the State of Florida as a limited liability company and with the Secretary of the State of California as a foreign corporation authorized to operate in California. IMDS, LLC is merging with White Science World Wide, LLC, a limited liability company organized under the laws of the State of Georgia. The merged companies will operate as a single entity as IMDS, LLC, a Florida limited liability company. | ||
Soca Networks Singapore (Soca) | ||
Pursuant to the terms of a letter of intent dated December 17, 2007, the Company has agreed to purchase 20% of Soca for a total purchase price of $750,000. Half of the purchase price has been advanced $375,000 to Soca as a down payment, pending completion of the agreement terms. The balance of $375,000 is to be paid through the issuance of 220,588 shares of the Companys common stock. The final agreement is currently being negotiated and management expects to close the agreement prior to year end. | ||
10. | LICENSED PATENTS | |
Teeth Whitening Patents | ||
In October 2004, the Company acquired from the inventor the exclusive, perpetual license to two issued United States patents which are applicable to several teeth whitening products currently being marketed by the Company. Pursuant to the terms of the license agreement, the Company was granted an exclusive, worldwide, perpetual license to manufacture, market, distribute and sell the products contemplated by the patents subject to the payment of $65,000 as reimbursement to the patent holder for legal and other costs associated with obtaining the patents, which was paid in October 2004, and royalties for each unit sold subject to an annual minimum royalty of $100,000 per year. The Company is amortizing the initial cost of $65,000 for these patents over a ten year period and accordingly has recorded $21,125 of accumulated amortization for this patent as of December 31, 2007. The Company accrues this royalty when it becomes payable to the inventory therefore no provision has been made for this obligation as of December 31, 2007. | ||
Universal Applicator Patent | ||
In September 2004, the Company entered into an agreement with Lident N.V. (Lident), a company controlled by Mr. De Vreese, the Companys Chairman, to obtain an option, exercisable through December 31, 2005, to license an international patent (excluding the US) and worldwide manufacturing and distribution rights for a potential new product which Lident had been assigned certain rights by the inventors of the products, who are unrelated parties, prior to Mr. De Vreese association with the Company. The patent is an Italian patent which relates to a single use universal applicator for dental pastes, salves, creams, powders, liquids and other substances where manual application could be relevant. The Company has filed to have the patent approved throughout Europe. The agreement required the Company to advance to the inventors through Lident a fully refundable deposit of 100,000 subject to the Companys due diligence regarding the enforceability of the patent and marketability of the product, which, if viable, would be assigned to the Company for additional consideration to the inventors of 100,000 and an ongoing royalty from sales of products related to the patent equal to 3% of net sales and, if not viable, the deposit would be repaid in full by Lident. The consideration the Company had agreed to pay Lident upon the exercise of the option is the same as the consideration Lident is obligated to pay the original inventors. Consequently, Lident would not have profited from the exercise of |
12
the option. Furthermore, at a meeting of the Companys Board of Directors on July 13, 2005, the Board accepted Lidents offer to facilitate an assignment of Lidents intellectual property rights to the technology to the Company in exchange for the reimbursement of Lidents actual costs incurred relating to the intellectual property. Consequently, when the Company exercises the option, all future payments, other than the reimbursement of costs would be paid directly to the original inventors and not to Lident. | ||
On December 12, 2005, the Company exercised the option and the Company and the patent holder agreed to revise the assignment agreement whereby the Company agreed to pay 50,000 additional compensation in the form of prepaid royalties instead of the 100,000 previously agreed, 25,000 of which had been paid by the Company in September 2005 and the remaining 25,000 to be paid upon the Companys first shipment of a product covered by the patent. The patent is being amortized over five (5) years and accordingly, the Company has recorded $50,297 of accumulated amortization for this patent as of December 31, 2007. At the end of December 31, 2007, the product has not yet been commercialized. Management believes no impairment is applicable. |
11. | LINE OF CREDIT | |
On October 8, 2004, our wholly owned subsidiary, Remedent N.V., obtained a mixed-use line of credit facility with Fortis Bank, a Belgian bank, for 1,070,000 (the Facility). The Facility was secured by a first lien on the assets of Remedent N.V. The purpose of the Facility is to provide working capital to grow our business and to finance certain accounts receivable as necessary. Since opening the Facility in 2004, Remedent N.V. and Fortis Bank have subsequently amended the Facility several times to increase or decrease the line of credit. On May 3, 2005 the Facility was amended to decrease the line of credit to 1,050,000. On March 13, 2006 the Facility was amended to increase the mixed-use line of credit to 2,300,000, consisting of a 1,800,000 credit line based on the eligible accounts receivable and a 500,000 general line of credit. The latest amendment to the Facility, dated September 1, 2006, amended and decreased the mixed-use line of credit to 2,050,000. Each line of credit carries its own interest rates and fees as provided in the Facility. Remedent N.V. is currently only utilizing two lines of credit, advances based on account receivables and the straight loan. As of December 31, 2007 and March 31, 2007, Remedent N.V. had, in the aggregate, $813,344 and $1,530,276 advances outstanding, respectively, under this mixed-use line of credit facility. | ||
12. | LONG TERM DEBT | |
On September 15, 2005, the Company entered into two five year capital lease agreements for manufacturing equipment totaling 70,296 (US $85,231). On October 24, 2006, the Company entered into another five year capital lease agreement for additional manufacturing equipment totaling 123,367 (US $157,503). The leases require monthly payments of principal and interest at 7.43% of 1,258 (US$1,852 at December 31, 2007) for the first two leases and 9.72% of 2,256 (US$3,321 at December 31, 2007) and provide for buyouts at the conclusion of the five year term of 2,820 (US$4,151) or 4.0% of original value for the first two contracts and 4,933 (US $7,262) or 4.0 % of the original value for the second contract. The book value as of December 31, 2007 and March 31, 2007 of the equipment subject to the foregoing leases are $161,811 and $198,225, respectively. | ||
13. | DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS | |
Balances due to related parties consist of the following: |
December 31, 2007 | March 31, 2007 | |||||||
Demand loan from a former officer and major stockholder
|
$ | 50,536 | $ | 50,536 | ||||
|
||||||||
|
$ | 50,536 | $ | 50,536 | ||||
|
Borrowings from employees and entities controlled by officers of the Company are, unsecured, non-interest bearing, and due on demand. | ||
Transactions with related parties consisted of the following: | ||
Compensation: | ||
During the nine month periods ended December 31, 2007 and 2006 respectively, the Company incurred $483,304 and $441,707 respectively, as compensation for all directors and officers. |
13
Effective August 8, 2007, the Company appointed a Senior Vice President and Head of U.S. Marketing. Terms of the appointment provide for an initial base salary of $150,000 per year and options to purchase 100,000 shares of common stock under the Companys 2004 Incentive and Nonstatutory Stock Option Plan (granted Refer to Note 16). | ||
Sales Transactions: | ||
One of the Companys directors owns a 5% interest in a client company, IMDS Inc. (refer to Note 9), to which goods were sold during the years ended March 31, 2007 and 2006 totaling $476,122 and $38,494 respectively, sales during the three month period ended December 31, 2007 totaled $ 47,256. Accounts receivable with this customer totaled $63,272 and $ 105,851 as at December 31, 2007 and 2006 respectively. | ||
All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties reflecting arms length consideration payable for similar services or transfers. | ||
Other related party transactions are disclosed in Supplemental Non-Cash Investing and Financing Activities, clause (e), and Note 17. (Refer to Note 9.) | ||
14. | ACCRUED LIABILITIES | |
Accrued liabilities are summarized as follows: |
December 31, 2007 | March 31, 2007 | |||||||
Accrued customer prepayments
|
$ | 12,401 | $ | | ||||
Accrued payroll and employee benefit taxes
|
167,234 | 260,676 | ||||||
Commissions
|
4,291 | 2,834 | ||||||
Accrued audit and tax preparation fees
|
19,000 | 27,282 | ||||||
Reserve for warranty costs
|
22,082 | 20,049 | ||||||
Accrued interest
|
1,289 | 6,180 | ||||||
Accrued consulting fees
|
11,701 | 2,528 | ||||||
Other accrued expenses
|
139,183 | 92,886 | ||||||
|
$ | 377,182 | $ | 412,435 | ||||
15. | CAPITAL STOCK | |
During the three months ended December 31, 2007 the Company received $15,900 on the exercise of 10,000 common stock purchase warrants. | ||
16. | EQUITY COMPENSATION PLANS | |
The Board of Directors and stockholders approved the Nonstatutory Stock Option Plan (the 2001 Plan) and adopted it on May 29, 2001. The Company has reserved 250,000 shares of its common stock for issuance to the directors, employees and consultants under the Plan. The Plan is administered by the Board of Directors. Vesting terms of the options range from immediately to five years. | ||
Pursuant to an Information Statement on Schedule 14C mailed on May 9, 2005 to all stockholders of record as of the close of business on February 1, 2005 and became effective September 3, 2005, the Company authorized the implementation of a 2004 Incentive and Nonstatutory Stock Option Plan (2004 Plan) reserving 800,000 shares of common stock for issuance to employees, directors and consultants of the Company or any subsidiaries. This plan became effective as of September 3, 2005 after the Company had completed a one for twenty reverse split. | ||
On October 1, 2006, the Company granted to a marketing consultant 25,000 options to purchase the Companys common stock at a price of $1.80 per share. These options vested immediately upon grant and are exercisable for a period of five years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 91.58%; risk free interest rate of 5% and an average life of 5 years resulting in a value of $1.298 per option granted. |
14
On September 14, 2006, pursuant to an S-8 filed with the SEC, the Company registered 1,150,000 common shares, pursuant to compensation arrangements. | ||
On August 17, 2007, pursuant to the terms of the Companys 2004 Plan, the Company granted to an employee 100,000 options to purchase the Companys common stock at a price of $1.50 per share. These options will vest over the next 3 years and are exercisable for a period of 5 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 5 years resulting in a value of $1.24 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $17,381 has been recorded in the period ended December 31, 2007. | ||
On September 21, 2007 the Company granted to employees and directors a total of 570,000 options to purchase the Companys common stock at a price of $1.75 per share. These options will vest over the next 3 years and are exercisable for a period of 10 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 7 years resulting in a value of $1.47 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $83,889 has been recorded in the period ended December 31, 2007. | ||
A summary of the option activity for the nine months ended December 31, 2007 pursuant to the terms of the plans is as follows: |
2001 Plan | 2004 Plan | Other | ||||||||||||||||||||||
Weighted | Weighted | Weighted | ||||||||||||||||||||||
Outstanding | Average | Outstanding | Average | Outstanding | Average | |||||||||||||||||||
Options | Exercise Price | Options | Exercise Price | Options | Exercise Price | |||||||||||||||||||
Options outstanding , March 31, 2007
|
222,500 | $ | 1.29 | 210,666 | $ | 3.19 | | | ||||||||||||||||
|
||||||||||||||||||||||||
Granted
|
| | 520,000 | 1.71 | 150,000 | $ | 1.75 | |||||||||||||||||
Exercised
|
| | | | | | ||||||||||||||||||
Cancelled or expired
|
| | | | | | ||||||||||||||||||
|
||||||||||||||||||||||||
Options outstanding, December 31,
2007
|
222,500 | $ | 1.29 | 730,666 | $ | 2.29 | 150,000 | $ | 1.75 | |||||||||||||||
|
||||||||||||||||||||||||
Options exercisable December 31,
2007
|
222,500 | $ | 1.29 | 210,666 | $ | 4.46 | | | ||||||||||||||||
|
||||||||||||||||||||||||
Exercise price range
|
$ | 1.00 to $4.00 | $ | 1.50 to $4.00 | $ | 1.75 | ||||||||||||||||||
|
||||||||||||||||||||||||
Weighted average remaining life
|
4.3 years | 5.62 years | 8.97 years | |||||||||||||||||||||
|
||||||||||||||||||||||||
Shares available for future issuance
|
27,500 | 69,334 | N/A | |||||||||||||||||||||
|
A summary of the Companys equity compensation plans approved and not approved by shareholders is as follows: |
Number of | Number of securities | |||||||||||
securities to be | remaining available for | |||||||||||
issued upon | future issuance under | |||||||||||
exercise of | Weighted-average | equity compensation | ||||||||||
of outstanding | exercise price of | plans (excluding | ||||||||||
options, warrants | outstanding options | securities reflected | ||||||||||
Plan Category | and right | warrants and rights | in column (a)) | |||||||||
Equity Compensation Plans approved by security holders
|
1,103,166 | $ | 2.01 | 96,834 | ||||||||
Equity Compensation Plans not approved by security holders
|
297,298 | $ | 1.50 | NA | ||||||||
|
||||||||||||
|
1,400,464 | $ | 1.91 | 96,834 | ||||||||
|
Prior to January 1, 2006, the Company accounted for employee stock-based compensation under the recognition and measurement principles of Accounting Principles Board Opinion (APB) No. 25, Accounting for Stock Issued to Employees, and related Interpretations, as permitted by SFAS No. 123, Accounting for Stock-Based Compensation. Under the recognition principles of APB No. 25, compensation expense related to restricted stock and performance units was recognized in the financial statements. However, APB No. 25 generally did not require the recognition of compensation expense for stock options because the exercise price of these instruments was generally equal to the fair value of the underlying common stock on the date of grant, and the related number of shares granted were fixed at that point in time. |
15
Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123(R), Share-Based Payment. In addition to recognizing compensation expense related to restricted stock and performance units, SFAS No. 123(R) also requires recognition of compensation expense related to the estimated fair value of stock options. The Company adopted SFAS No. 123(R) using the modified-prospective-transition method. Under that transition method, compensation expense recognized subsequent to adoption includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the values estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair values estimated in accordance with the provisions of SFAS No. 123(R). Consistent with the modified-prospective-transition method, the Companys results of operations for prior periods have not been adjusted to reflect the adoption of FAS 123(R). For the nine months) ended December 31, 2007 the Company recognized $101,270 (2006 $221,959) in compensation expense in the consolidated statement of operations. | ||
17. | COMMON STOCK WARRANTS AND OTHER OPTIONS | |
On February 10, 2006, the Company issued to an individual the right to purchase 150,000 shares of the Companys common stock at an exercise price of $2.60 per share for a term of five (5) years pursuant to the terms and conditions of a Stock Option Agreement as consideration for past services performed and the release of any and all claims under this individuals prior agreements with the Company. The 150,000 options have been valued in accordance with the Black-Scholes pricing model utilizing an historic volatility factor of 1.55, a risk free interest rate of 4.5% and an expected life for the options of five years, resulting in a value of $2.41 per option granted for a total for the warrants of $361,500. The value of this option grant was recorded as of December 31, 2005 as a research and development expense. | ||
In November 2006, the Company entered into a Settlement Agreement and Release (Settlement Agreement) with this individual pursuant to which the prior agreement was terminated. In connection with the Settlement Agreement, the Company agreed to pay this individual $65,000 in settlement of all accounts which was recorded as an expense as of the date of the Settlement Agreement and he in turn agreed to the cancellation of his options to purchase 150,000 shares of the Companys common stock in exchange for certain product rights that the Company had elected not to pursue. | ||
As of December 31, 2007, the Company has 7,260,026 warrants to purchase the Companys common stock outstanding that were not granted under shareholder approved equity compensation plans at prices ranging between $1.20 and $3.00 per share with expiration dates between August 2007 and September 2012 as follows: |
Weighted | ||||||||
Outstanding | Average Exercise | |||||||
Warrants | Price | |||||||
Warrants and options outstanding , March 31, 2007
|
3,105,651 | $ | 1.72 | |||||
Granted
|
4,200,000 | 1.55 | ||||||
Exercised
|
(10,000 | ) | 1.59 | |||||
Cancelled or expired
|
(35,725 | ) | | |||||
|
||||||||
Warrants exercisable December 31, 2007
|
7,260,026 | $ | 1.67 | |||||
|
||||||||
Exercise price range
|
$ | 1.20 to $10.00 | ||||||
|
||||||||
Weighted average remaining life
|
4.95 Years | |||||||
|
18. | SEGMENT INFORMATION | |
The Companys only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., Sylphar N.V., and Remedent Asia. Since the Company only has one segment, no further segment information is presented. |
December 31, 2007 | December 31, 2006 | |||||||
U.S. sales
|
$ | 316,208 | $ | 173,733 | ||||
Foreign sales
|
4,137,691 | 4,696,428 | ||||||
|
$ | 4,453,899 | $ | 4,870,161 | ||||
16
19. | COMMITMENTS AND CONTINGENCIES | |
Real Estate Lease | ||
The Company leases its 26,915 square feet office and warehouse facility in Deurle, Belgium from an unrelated party pursuant to a nine year lease commencing December 20, 2001 at a base rent of $6,838 per month ($9,696 per month at December 31, 2007). In addition, the Company is responsible for the payment of annual real estate taxes for the property which totaled 3,245 ($4,382) for calendar year 2006. The minimum aggregate rent to be paid over the remaining lease term based upon the conversion rate for the at December 31, 2007 is $283,142. Rent expense for the foregoing lease for the nine months ended December 31, 2007 and December 31, 2006 was $80,991 and $59,040 respectively. | ||
Minimum monthly lease payments for real estate, and all other leased equipment for the next four years are as follows based upon the conversion rate for the (Euro) at December 31, 2007. |
March 31, 2008
|
$ | 231,425 | ||
March 31, 2009
|
$ | 212,805 | ||
March 31, 2010
|
$ | 68,954 | ||
March 31, 2011
|
$ | 37,790 |
The discussion contained herein is for the nine months ended December 31, 2007 and 2006. The following discussion should be read in conjunction with the Companys condensed consolidated financial statements and the notes to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007. In addition to historical information, this section contains forward-looking statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors. Factors that could cause or contribute to any differences are discussed in Risk Factors and elsewhere in the Companys annual report on Form 10-KSB filed on July 13, 2007 with the Securities and Exchange Commission. Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007. The information contained in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007 is not a complete description of the Companys business or the risks associated with an investment in the Companys common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007 and in the Companys other filings with the Securities and Exchange Commission. |
17
For the three months ended | For the nine months ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2007 | 2006 | 2007 | 2006 | |||||||||||||
NET SALES
|
100.00 | % | 100.00 | % | 100.00 | % | 100.00 | % | ||||||||
COST OF SALES
|
58.20 | % | 57.96 | % | 58.23 | % | 53.96 | % | ||||||||
|
||||||||||||||||
GROSS PROFIT
|
41.80 | % | 42.04 | % | 41.77 | % | 46.04 | % | ||||||||
|
||||||||||||||||
OPERATING EXPENSES
|
||||||||||||||||
Research and development
|
8.07 | % | 5.47 | % | 5.56 | % | 6.24 | % | ||||||||
Sales and marketing
|
28.65 | % | 10.33 | % | 22.38 | % | 15.26 | % | ||||||||
General and administrative
|
50.98 | % | 75.21 | % | 64.91 | % | 52.22 | % | ||||||||
Depreciation and amortization
|
3.76 | % | 5.17 | % | 4.85 | % | 3.03 | % | ||||||||
|
||||||||||||||||
TOTAL OPERATING EXPENSES
|
91.46 | % | 96.18 | % | 97.70 | % | 76.75 | % | ||||||||
|
||||||||||||||||
LOSS FROM OPERATIONS
|
(49.66 | )% | (54.14 | )% | (55.93 | )% | (30.71 | )% | ||||||||
|
||||||||||||||||
Other income (expense)
|
(0.35 | )% | (1.71 | )% | 0.65 | % | 0.67 | % | ||||||||
|
||||||||||||||||
LOSS BEFORE INCOME TAXES
|
(50.01 | )% | (55.85 | )% | (55.28 | )% | (30.04 | )% | ||||||||
|
||||||||||||||||
NET INCOME (LOSS)
|
(50.01 | )% | (55.85 | )% | (55.28 | )% | (30.04 | )% | ||||||||
|
18
19
20
21
1 | The following four directors were elected to hold office for one-year terms or until their successors are elected and qualified: |
Votes Against | ||||||||||||
Votes For | or Withheld | Total Voted | ||||||||||
Guy De Vreese
|
16,783,357 | 2,657 | 16,786,014 | |||||||||
Robin List
|
16,783,357 | 2,657 | 16,786,014 | |||||||||
Stephen Ross
|
16,784,325 | 721 | 16,785,046 | |||||||||
Fred Kolsteeg
|
16,784,325 | 721 | 16,785,046 |
2. | To approve adoption of the 2007 Equity Incentive Plan: |
For
|
15,719,684 | |||
Against
|
23,410 | |||
Abstain
|
1,500 |
3. | To ratify the Board of Directors appointment of PKF Bedrijfsrevisoren as the Companys independent registered accounting firm for the 2008 fiscal year. |
For
|
16,780,168 | |||
Against
|
2,002 | |||
Abstain
|
2,810 |
22
31.1
|
Certifications of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act | |
|
||
31.2
|
Certifications of Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act | |
|
||
32.1
|
Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act | |
|
||
32.2
|
Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act |
23
|
REMEDENT, INC. | |
Dated: February 13, 2008
|
/s/ Robin List | |
|
||
|
By: Robin List | |
|
Its: Chief Executive Officer (Principal Executive Officer) and Director | |
|
||
Dated: February 13, 2008
|
/s/ Philippe Van Acker | |
|
||
|
By: Philippe Van Acker | |
|
Its: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
24
31.1 | Certifications of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act | |
31.2 | Certifications of Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act | |
32.1 | Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act | |
32.2 | Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act |
25
1 Year Elysee Development (PK) Chart |
1 Month Elysee Development (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions